Education
About Us
Working with TipRanks
Follow Us
RHON-KLINIKUM AG (DE:RHK)
:RHK
Top Page
RHON-KLINIKUM AG
(LSE:RHK)
Rating:65Neutral
Price Target:
€14.00
▲(13.82%Upside)
RHON-KLINIKUM AG (RHK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€823.34M
Dividend YieldN/A
Average Volume (3M)2.56K
Price to Earnings (P/E)21.6
Beta (1Y)0.05
Revenue Growth12.23%
EPS Growth-8.23%
CountryDE
Employees18,819
SectorHealthcare
Sector Strength41
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.11
Shares Outstanding66,962,470
10 Day Avg. Volume2,099
30 Day Avg. Volume2,557
Financial Highlights & Ratios
PEG Ratio-4.67
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio27.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
RHON-KLINIKUM AG Business Overview & Revenue Model
Company DescriptionRHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. It operates eight hospitals and 5,420 beds/places at five medical sites. The company is based in Bad Neustadt an der Saale, Germany.
How the Company Makes MoneyRHÖN-KLINIKUM AG primarily generates revenue through the provision of healthcare services. This includes income from inpatient and outpatient care, surgical procedures, diagnostic services, and rehabilitation programs. The company receives payments from a variety of sources, including public and private health insurance providers, government healthcare programs, and direct patient payments. Additionally, RHÖN-KLINIKUM AG may engage in partnerships with other healthcare organizations, research institutions, and technology providers to enhance its service offerings and operational efficiency, contributing to its revenue streams.
RHON-KLINIKUM AG Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.43B | 1.73B | 1.45B | 1.40B | 1.36B | 1.30B | Gross Profit |
| 992.77M | 202.88M | 999.52M | 971.62M | 937.72M | 895.98M | EBIT |
| 37.31M | 40.40M | 36.11M | 30.52M | 10.60M | 56.80M | EBITDA |
| 106.63M | 116.58M | 106.15M | 100.21M | 80.66M | 125.56M | Net Income Common Stockholders |
| 32.09M | 38.71M | 25.14M | 28.30M | 2.46M | 43.28M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 225.61M | 342.84M | 304.93M | 299.72M | 266.15M | 235.69M | Total Assets |
| 1.81B | 1.77B | 1.70B | 1.67B | 1.63B | 1.63B | Total Debt |
| 143.45M | 149.84M | 158.20M | 159.76M | 160.60M | 172.20M | Net Debt |
| -82.16M | -56.20M | 80.87M | 33.45M | 69.65M | 44.51M | Total Liabilities |
| 519.83M | 490.30M | 453.51M | 440.82M | 439.45M | 446.11M | Stockholders Equity |
| 1.26B | 1.25B | 1.22B | 1.20B | 1.17B | 1.16B |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | 46.20M | -16.90M | 19.70M | 16.30M | -67.20M | Operating Cash Flow |
| 0.00 | 109.00M | 41.30M | 97.50M | 113.30M | 47.30M | Investing Cash Flow |
| 0.00 | 40.90M | -86.20M | -58.30M | -135.20M | -86.70M | Financing Cash Flow |
| 0.00 | -21.20M | -4.10M | -3.90M | -15.10M | 35.10M |
RHON-KLINIKUM AG Technical Analysis
Negative
12.30
Price Trends
13.73
Negative
13.89
Negative
13.27
Negative
Market Momentum
-0.38
Negative
44.82
Neutral
8.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RHK, the sentiment is Negative. The current price of 12.3 is below the 20-day moving average (MA) of 12.82, below the 50-day MA of 13.73, and below the 200-day MA of 13.27, indicating a bearish trend. The MACD of -0.38 indicates Negative momentum. The RSI at 44.82 is Neutral, neither overbought nor oversold. The STOCH value of 8.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:RHK.
RHON-KLINIKUM AG Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €823.34M | 21.59 | 3.09% | ― | 12.23% | -8.23% | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% | |
| €140.60M | 5.36 | 12.45% | ― | ― | ― | ||
| €32.71M | ― | ― | ― | ― | |||
| €97.93M | 31.66 | 18.60% | ― | ― | ― | ||
| €4.62M | 1.46 | 29.97% | ― | ― | ― | ||
| €265.60M | 16.47 | 14.61% | 3.52% | ― | ― |
* Healthcare Sector Average
Performance Comparison
DE:RHK
RHON-KLINIKUM AG
12.80
0.70
5.79%
GB:0NDG
MEDICLIN
2.94
-2.31
-44.00%
DE:MAK
MATERNUS-Kliniken AG
1.56
-0.14
-8.24%
DE:LIK
Limes Schlosskliniken AG
332.00
-18.00
-5.14%
DE:EIF
Eifelhoehen-Klinik AG
1.48
0.17
12.98%
DE:M12
M1 Kliniken AG
14.64
-5.08
-25.76%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.